A Phase 2 interventional study of Ketamine and saline and Active Placebo (Midazolam) Infusion in Late Life Depression (LLD), MCI and MCI-AD, Early Stage Alzheimer's Disease, sponsored by Vanderbilt University Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Vanderbilt University Medical Center · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 319 studies in Depressive Disorder with a site in United States — 39 open to participants now, 45 under way, 2 of them phase 3. Depressive Disorder · United States.
Among the 319 studies in Depressive Disorder with a site in United States, this one is the 209th largest by planned enrollment of the 275 interventional ones that give a count, is one of 11 that started in 2026, is one of 49 in phase 2, reaches primary completion later than 39 of the 44 other live ones, and was the 319th registered.
855 studies on the registry are indexed under Depressive Disorder; 159 are open to participants now.
Browse Depressive Disorder studies →39 of the 319 studies in Depressive Disorder with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Brazil and 12 more countries
Ages 18–75
Ksana Health · Sites in United States
Ages 13–24
University of California, San Diego · Sites in United States
Ages 18–65
Mayo Clinic · Sites in United States
Ages 12–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
319 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 61 · Phase 3 41 · Phase 4 34
First in 1988; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 88 across 689 interventional studies indexed under Depressive Disorder.
Median enrollment 85 across the 275 interventional studies, 149 across the 40 observational. Of the 259 that completed or were terminated, 98 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 319 have an industry lead sponsor. The 10 most frequent:
Vanderbilt University Medical Center is the lead sponsor of 835 studies on the registry; 155 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.
Vanderbilt University Medical Center has 4 studies filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
16 of the studies in Depressive Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07841483Slingshot AIAI Mental Health Tool vs. Psychoeducation Control | 2026-12 |
| NCT06508450New York UniversityA Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults | 2026-12 |
| NCT05282277University of North Carolina, Chapel HillExamining the Effects of Estradiol on Neural and Molecular Response to Reward | 2026-12-31 |
| NCT05920252Ksana HealthA Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide | 2026-12-31 |
| NCT05011864University of Texas at AustinIntegrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 319 studies in Depressive Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dementia is one of the major causes of disability and among older adults globally, with 6.7 million Americans living with Alzheimer's disease. Depression is common in people with cognitive and memory problems.
Depression in the elderly increases the risk of disability, medical comorbidity, cognitive impairment, and death. Patients with depression are at an increased risk of worsening cognition. Further, patients with depression are traditionally excluded from therapeutic trials in Alzheimer's Disease and other dementias. Current medications to treat depression in patients with dementia haven't been helpful. Effective approaches to treating depression in dementia are necessary.
Ketamine has been studied extensively for the treatment of depression. It produces a rapid antidepressant effect with improvement of depressive symptoms reported 2 hours after infusion that continues for several days. Due to its rapid action, ketamine has gathered significant public attention. Providers in the community are already administering this drug to patients with dementia based on anecdotal evidence without evidence of its safety or benefit. A fast, safe, and effective treatment of depression may reduce the rate of cognitive decline in patients with dementia and reduce depression burden and improve quality of life and function. As patients with depression are likely unable to receive disease modifying therapies for Alzheimer's Disease (lecanemab or donanemab) rapid improvement of depressive symptoms with ketamine could represent treatment that allows them to be able to receive these therapies faster.
This proposal, will examine the safety, tolerability and feasibility of administering IV ketamine for the treatment of depression in participants with Alzheimer's Disease as well as obtain preliminary data regarding the treatment benefit.
Due to its rapid action, ketamine has gathered significant public attention. Providers in the community are already administering this drug to patients with dementia based on anecdotal evidence without evidence of its safety or benefit. A fast, safe, and effective treatment of depression may reduce the rate of cognitive decline in patients with dementia, but will also reduce neuropsychiatric symptom burden and improve quality of life and function. As patients with moderate to severe depression are likely unable to receive lecanemab or donanemab for treatment of AD, rapid improvement of depressive symptoms with ketamine could represent treatment that allows them to be able to receive disease-modifying therapies faster.
This proposed study will collect preliminary data on the safety, tolerability, and feasibility of administering IV ketamine for the treatment of depression in participants with MCI or mild dementia. It will also obtain preliminary data regarding the magnitude and duration of treatment benefit. If the hypothesis is validated, this project will support further studies including a multisite randomized double-blinded control trial examining ketamine as a novel treatment for depression in ADRD populations.
Primary Aim 1: To evaluate the feasibility, safety, tolerability, and acceptability of administering IV ketamine to participants with MCI or mild dementia due to AD.
Hypothesis 1: Ketamine administration will be acceptable, feasible, well tolerated, and safe as measured by 90% or greater completion rate, adverse events, change in vital signs, acceptability measures, and a Clinician Administered Dissociative States Scale (CADSS) score of \< 4 at 40 minutes post infusion.
Secondary Aim 2: To obtain preliminary evidence regarding the effects of ketamine on symptoms of depression in participants with MCI or mild dementia due to AD.
Hypothesis 1: Compared to the placebo control group, ketamine will lead to greater improvement in depression symptoms as determined by 50% or greater reduction in baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score at 2 weeks (secondary outcome).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ketamine and saline
Drug: Active Placebo (Midazolam) Infusion
Ketamine will be infused over 40 min twice weekly for two weeks. Ketamine will be calculated as 0.5mg/kg.
Also known as: Ketamine (0.5 mg/kg)
Active placebo (midazolam) will be infused over 40 min twice weekly for two weeks. Active placebo (midazolam) dose will be calculated as 0.02mg/kg.
Feasibility of the Study as Measured by the Number of Participants Completing the Study
Study feasibility will be evaluated by the number of participants who complete all required study visits and procedures through the final Week 8 visit. A greater number of participants completing all study requirements will indicate greater feasibility of the study procedures and participant retention.
Time frame: From enrollment to the end of safety monitoring at 8 weeks
Safety, as Measured by the Number of Participants with At Least One Treatment-Emergent Adverse Event
The number of participants experiencing at least one treatment-emergent adverse event during the study will be recorded. Adverse events will be monitoring and documented through the study, including assessment of event severity and relationship to study intervention.
Time frame: From the first medication infusion through study completion at 8 weeks
Clinician-Administered Dissociative States Scale (CADSS) Total Score
Dissociative symptoms will be assessed using the Clinician-Administered Dissociative States Scale (CADSS). Possible scores range from 0-92, with higher scores indicating greater severity of dissociative symptoms.
Time frame: Week 1 Infusion 1, Week 1 Infusion 2, Week 2 Infusion 1, and Week 2 Infusion 2 prior to and 40 and 90 minutes after the start of each infusion.
Severity of Suicidal Thoughts with Montgomery-Åsberg Depression Rating Scale (MADRS) Item 10 Score
Suicidal thoughts will be assessed using Item 10 (Suicidal Thoughts) of the Montgomery-Åsberg Depression Rating Scale (MADRS). Scores range from 0 to 6, with higher scores indicating greater severity of suicidal thoughts.
Time frame: From enrollment to the end of safety monitoring at 8 weeks
Change in Severity of Suicidal Ideation as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Suicidal ideation will be assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). The highest level of suicidal ideation encorsed will be recorded using the C-SSRS severity categories ranging from 1 (wish to be dead) to 5 (suicidal intent with a specific plan). Change from baseline will be evaluated by comparing the highest level of suicidal ideation endorsed at follow-up assessments with the screening assessment. Higher scores indicate greater severity of suicidal ideation.
Time frame: Screening (baseline), Week 1 Infusion 2, Week 2 Infusion 2
Change in Suicidal Behavior as Measured by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Suicidal behavior will be assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). The presence of suicidal behavior, including actual, interrupted, or aborted suicide attempts and preparatory acts, will be recorded. Change from baseline will be evaluated by comparing the presence or absence of suicidal behavior at follow-up assessments with baseline. The number of participants reporting suicidal behavior will be summarized at each assessment.
Time frame: Screening (baseline), Week 1 Infusion 2, Week 2 Infusion 2
Number of Treatment-Emergent Side Effects as Measured by the Treatment-Emergent Symptom Scale (TESS)
The Treatment-Emergent Symptom Scale (TESS) will be used to assess treatment-emergent side effects. The number of symptoms reported by participants will be recorded at summarized at each assessment.
Time frame: Week 1 (Infusions 1 and 2), Week 2 (Infusions 1 and 2), Week 3, Week 4, and Week 8
Severity of Treatment-Emergent Side Effects as Measured by the Treatment-Emergent Symptom Scale (TESS)
The severity of treatment-emergent side effects reported by participants will be assessed using the Treatment-Emergent Symptoms Scale (TESS). Symptom severity ratings will be recorded and summarized at each assessment.
Time frame: Week 1 (Infusions 1 and 2), Week 2 (Infusions 1 and 2), Week 3, Week 4, and Week 8
Acceptability of the intervention as measured by the Acceptability of Intervention Measure (AIM)
The Acceptability of Intervention Measure (AIM) is a 4-item self-report measure used to assess participants' perceptions of the acceptability of the intervention. Each item is rated on a 5-point Likert scale (1-5), with higher scores indicating a greater perceived acceptability of the intervention.
Time frame: Week 4 (approximately 2 weeks after the final medication infusion)
Change in MADRS (Montgomery Asberg Depression Rating Scale) Score
The MADRS total score range is 0-60, where higher scores indicate greater depression severity. 50% improvement in MADRS score is clinically meaningful and it is a standard used across depression trials to measure response to treatment.
Time frame: Week 1 Infusion 2 and Week 2 Infusion 2
Plan to share: Yes — This study will include clinical and cognitive data from older depressed subjects. The final dataset will include clinical information about subject psychiatric diagnoses, psychiatric and medical history, cognitive data, and response to ketamine. The investigators will share data via the National Database for Clinical Trials related to Mental Illness (NDCT). NDCT provides a secure platform for data-sharing allowing for communication of research data, tools, and supporting documents. As required by NDCT, the investigators will obtain a Global Unique Identifier (GUID) for each participant. The investigators will additionally follow NDCT requirements to certify and review data, as well as timeline requirements for data submission and data sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be shared according to policies from the NDCT and NDA (NIMH Data Archive). Descriptive data, outcome measures and analyzed data will be shared will be shared within 4 months of when a publication is accepted. Study data will be shared through the NDCT indefinitely
Access criteria: The NIH will provide access to scientific investigators for research purposes. Qualified researchers who have completed a Data Use Certification and received approval from the NDA Data Access Committee (DAC) may be approved to access broadly shared data. A separate request process exists for access to data in federated sources. Additionally, the DAC and support staff at NIH have access to NDA shared data.
Data sharing details ↗ · nda.nih.gov
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.
Of 43 phase 2 interventional studies under Depressive Disorder, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 36 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vanderbilt University Medical Center →